Keyphrases
Clinical Trials
100%
Multiple Sclerosis
100%
Good Recovery
100%
Relapse Recovery
100%
Treatment Delay
45%
Expanded Disability Status Scale
45%
Disease-modifying Therapy
27%
Hazard Ratio
27%
Therapy Initiation
18%
Benign Disease
18%
Immediate Treatment
18%
Placebo-controlled
9%
Extension Trial
9%
Placebo
9%
Evidence-based
9%
Long-term Treatment
9%
Disability
9%
Early Recovery
9%
Disease Course
9%
Symptom Onset
9%
Treatment Initiation
9%
Kaplan-Meier
9%
Long-term Disability
9%
Clinically Isolated Syndrome
9%
Interferon beta-1a
9%
Disability Accumulation
9%
Medicine and Dentistry
Expanded Disability Status Scale
100%
Multiple Sclerosis Clinical Trial
100%
Hazard Ratio
60%
Disease Modifying Therapy
60%
Multiple Sclerosis
60%
Benign Tumor
40%
Placebo
40%
Disease Course
20%
Clinically Isolated Syndrome
20%
Beta1a Interferon
20%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Expanded Disability Status Scale
100%
Multiple Sclerosis
100%
Diseases
80%
Placebo
40%
Beta1a Interferon
20%
Disease Course
20%
Demyelinating Disease
20%